Combined expression of p53, Bcl-2, and p21WAF-1 proteins in lung cancer and premalignant lesions: Association with clinical characteristics

Lung

Volumn 179, Issue 5, 2001, Pages 265-278

  Kalomenidis, Ioannis ^a   Orphanidou, Dora ^a   Papamichalis, George ^b   Vassilakopoulos, Theodoros ^a   Skorilas, Andreas ^c   Rasidakis, Antonis ^a   Papastamatiou, Hera ^b   Jordanoglou, John ^a   Roussos, Charis ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Sixth Pulmonary Clinic   (Greece)

^c Papanikolaou Res Center of Oncology   (Greece)

Author keywords

Bcl 2; Immunohistochemistry; Lung cancer; p21WAF 1; p53; Preneoplastic

Indexed keywords

PROTEIN BCL 2; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; BRONCHOSCOPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CIGARETTE SMOKING; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERPLASIA; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG DYSPLASIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRECANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SQUAMOUS CELL METAPLASIA;

AGED; AGED, 80 AND OVER; BRONCHI; CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SMOKING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035734719     PISSN: 03412040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004080010067     Document Type: Article

References (40)

1. p53 mutant immunophenotype and deregulation of p53 transcription pathway (bcl2, Bax, Waf1) in precursor bronchial lesions of lung cancer
2. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma
3. p21 waf1/Cip1mda-6 expression in non-small-cell lung cancer: Relationship to survival
4. The biology of lung cancer
5. Sequential molecular genetic changes in lung cancer development
6. Does immunointensity account for the difference in prognostic significance of Bcl-2 expression in non-small cell lung cancer?
7. Bcl-2 expression in non-small cell lung cancers: Higher frequency of expression in squamous cell carcinomas with earlier pT status
8. p53 expression in non-small cell lung cancer: Clinical and biological correlations
9. Bcl-2: A prognostic factor inversely correlated to p53 in non-small-cell lung cancer
10. Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis
11. Prognostic significance of p53 and rasp21 expression in nonsmall cell lung cancer
12. K-ras and p53 mutations are an independent unfavorable prognostic indicator in patients with non-small-cell lung cancer
13. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas. Relationship with p53 and MDM2 protein expression
14. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs)
15. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
16. p53 in tumor pathology: Can we trust immunohistochemistry? - Revisited!
17. The use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures
18. Increased expression of mutant forms of p53 oncogene in primary lung cancer
19. Clinical significance of p53 in non-small cell lung cancer
20. Bcl-2 initiates a new category of oncogenes: Regulators of cell death
21. p53, the guardian of the genome
22. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage
23. p21 RNA and protein expression in non-small cell lung carcinomas: Evidence of p53-independent expression in and association with tumoral differentiation
24. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: A metaanalysis
25. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vitro
26. p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: An analysis of medically treated patients
27. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers
28. Immunohistochemical detection of p53 protein in neoplastic, preneoplastic and normal bronchial mucosa specimens obtained during diagnostic bronchoscopy
29. Epidemiology of lung cancer in two different periods of time, ten years apart, in Greece
30. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression
31. Tumor suppressor p53 mutations and breast cancer: A critical analysis
32. Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer
33. p53 immunohistochemistry can identity bronchial dysplastic lesions proceeding to lung cancer: A prospective study
34. Molecular and genetic aspects of lung cancer
35. Development of carcinoma of the lung as reflected in exfoliated cells
36. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer
37. Genomic instability and the role of p53 mutations in cancer cells
38. Clinical and pathological associations with p53 tumour suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma
39. Histological typing of tumors of lung and pleura
40. Outcome of bronchial carcinoma in situ